Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2015Journal of Cerebral Blood Flow & MetabolismOpen Access

Angiotensin-(1-7) Protects against the Development of Aneurysmal Subarachnoid Hemorrhage in Mice

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does Angiotensin-(1-7) prevent the rupture of intracranial aneurysms in a mouse model?

Population

Mouse model of intracranial aneurysms in which aneurysmal rupture occurs spontaneously and causes neurologic…

Comparison

Angiotensin- started 6 days after aneurysm… vs Control/untreated mice (implied).

Design

Preclinical

Follow-up

2 weeks

Authors

KSKenji ShimadaTokushima UniversityHFHajime FurukawaBarrow Neurological InstituteKWKosuke WadaHyogo University

Discussion

Loading...

Member takes

Implication

No immediate clinical implications; leaves open translation of AT2R-mediated rupture protection to human aneurysmal subarachnoid hemorrhage.

Structured PICO

Does Angiotensin-(1-7) prevent the rupture of intracranial aneurysms in a mouse model?

P
Population
Mouse model of intracranial aneurysms (including AT2R knockout mice) in which aneurysmal rupture occurs spontaneously and causes neurologic symptoms.
I
Intervention
Angiotensin-(1-7) (0.5 mg/kg/day) started 6 days after aneurysm induction and continued for 2 weeks, with or without Mas receptor antagonist (A779 0.5 mg/kg/day or 2.5 mg/kg/day) or AT2R antagonist (PD 123319, 10 mg/kg/day).
C
Comparator
Control/untreated mice (implied).
O
Outcome
Rupture rate of intracranial aneurysms.surrogate

Angiotensin-(1-7) protects against intracranial aneurysm rupture in mice through an AT2R-dependent mechanism, highlighting a potential therapeutic pathway for preventing aneurysmal subarachnoid hemorrhage.

Cite This Study

Shimada et al. (2015) studied this question.

synapsesocial.com/papers/6a81e082c78e0b043bd82bbahttps://doi.org/10.1038/jcbfm.2015.30
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lack of Specificity of Commercial Antibodies Leads to Misidentification of Angiotensin Type-1 Receptor Protein2013 · 31 citations
  2. 2Angiotensin-(1–7) Dose-Dependently Inhibits Atherosclerotic Lesion Formation and Enhances Plaque Stability by Targeting Vascular Cells2013 · 64 citations
  3. 3Differential Mechanisms of Ang (1‐7)‐Mediated Vasodepressor Effect in Adult and Aged Candesartan‐Treated Rats2011 · 42 citations
  4. 4Short-Term Angiotensin(1-7) Receptor Mas Stimulation Improves Endothelial Function in Normotensive Rats2005 · 108 citations
  5. 5Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways2006 · 566 citations